{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:37:19Z","timestamp":1768898239933,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.numecd.2011.11.005","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T12:32:13Z","timestamp":1330000333000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Glitazones in chronic kidney disease: Potential and concerns"],"prefix":"10.1016","volume":"22","author":[{"given":"D.","family":"Bolignano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2011.11.005_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2011.11.005_bib2","series-title":"National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011","author":"U.S. Department of Health and Human Services, Centers for Disease Control and Prevention","year":"2011"},{"key":"10.1016\/j.numecd.2011.11.005_bib3","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.106.613828","article-title":"Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham heart study","volume":"113","author":"Fox","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2011.11.005_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2011.11.005_bib5","doi-asserted-by":"crossref","first-page":"51B","DOI":"10.1016\/j.amjcard.2006.11.006","article-title":"Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk","volume":"99","author":"Uwaifo","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2011.11.005_bib6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1210\/jc.2006-1910","article-title":"Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone","volume":"92","author":"Wajcberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2011.11.005_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacc.2010.06.055","volume":"57","author":"Nicholls","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2011.11.005_bib8","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2011.11.005_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ahj.2006.11.005","article-title":"A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes","volume":"153","author":"Stocker","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2011.11.005_bib10","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2011.11.005_bib11","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.298.22.2634","article-title":"Thiazolidinediones and cardiovascular outcomes in older patients with diabetes","volume":"298","author":"Lipscombe","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2011.11.005_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2011.11.005_bib13","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2011.11.005_bib14","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2011.11.005_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2011.11.005_bib16","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2011.11.005_bib17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.164.19.2097","article-title":"A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors","volume":"164","author":"Chiquette","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.numecd.2011.11.005_bib18","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","article-title":"Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation","volume":"121","author":"Kaul","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2011.11.005_bib19","unstructured":"United States Renal Data System; 2011 Annual Data Report available at: http:\/\/www.usrds.org\/adr.aspx. [accessed 05.10.11]."},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2011.11.005_bib20","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.2215\/CJN.05210709","article-title":"The databases: renal replacement therapy since 1989\u2013the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)","volume":"4","author":"Zoccali","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2011.11.005_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.2007060678","article-title":"Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease","volume":"19","author":"Schneider","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2011.11.005_bib22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/ki.2009.4","article-title":"Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes","volume":"75","author":"Brunelli","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.numecd.2011.11.005_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2008060579","article-title":"Rosiglitazone is associated with mortality in chronic hemodialysis patients","volume":"20","author":"Ramirez","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2011.11.005_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MNH.0b013e32833e4ce1","article-title":"Albuminuria: all you need to predict outcomes in chronic kidney disease?","volume":"19","author":"Gansevoort","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.numecd.2011.11.005_bib25","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.2337\/db09-0407","article-title":"Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT","volume":"58","author":"De Cosmo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2011.11.005_bib26","doi-asserted-by":"crossref","first-page":"F1036","DOI":"10.1152\/ajprenal.0025.2001","article-title":"Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature","volume":"281","author":"Guan","year":"2001","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.numecd.2011.11.005_bib27","doi-asserted-by":"crossref","first-page":"F639","DOI":"10.1152\/ajprenal.00189.2001","article-title":"Upregulation of type 1 collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation","volume":"282","author":"Zheng","year":"2002","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.numecd.2011.11.005_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00467-010-1602-2","article-title":"PPAR\u03b3 and chronic kidney disease","volume":"26","author":"Fogo","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.numecd.2011.11.005_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.HYP.37.2.722","article-title":"Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells","volume":"37","author":"Nicholas","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2011.11.005_bib30","first-page":"1040","article-title":"Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats","volume":"117","author":"Dong","year":"2004","journal-title":"Chin Med J (England)"},{"key":"10.1016\/j.numecd.2011.11.005_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.numecd.2011.11.005_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1440-1797.2009.01253.x","article-title":"Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice","volume":"15","author":"Higashi","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.numecd.2011.11.005_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1681\/ASN.V132342","article-title":"Biphasic vasodilator action of troglitazone on the renal microcirculation","volume":"13","author":"Arima","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2011.11.005_bib34","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.2174\/092986710793348581","article-title":"Oxidative stress in diabetic nephropathy","volume":"17","author":"Kashihara","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.numecd.2011.11.005_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/CS20070462","article-title":"Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential","volume":"116","author":"Yang","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.numecd.2011.11.005_bib36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.lfs.2003.03.004","article-title":"Effect of the new thiazolidinedione\u2013pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits","volume":"74","author":"Gumieniczek","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.numecd.2011.11.005_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/CS20100113","article-title":"Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats","volume":"119","author":"Dai","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.numecd.2011.11.005_bib38","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2337\/diacare.21.12.2135","article-title":"Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy","volume":"21","author":"Imano","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2011.11.005_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1464-5491.2001.00463.x","article-title":"Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria","volume":"18","author":"Nakamura","year":"2001","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2011.11.005_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.27.1.141","article-title":"One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes","volume":"27","author":"Hanefeld","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2011.11.005_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","article-title":"Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study","volume":"21","author":"Matthews","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2011.11.005_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.metabol.2003.10.025","article-title":"Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes","volume":"53","author":"Yanagawa","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2011.11.005_bib43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2011.11.005_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.jhh.1001444","article-title":"Rosiglitazone reduces urinary albumin excretion in type II diabetes","volume":"17","author":"Bakris","year":"2003","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.numecd.2011.11.005_bib45","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","article-title":"Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients","volume":"54","author":"Pistrosch","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2011.11.005_bib46","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/01.hjh.0000244955.39491.88","article-title":"Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria","volume":"24","author":"Bakris","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2011.11.005_bib47","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.clinthera.2007.09.011","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.numecd.2011.11.005_bib48","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2011.11.005_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3904\/kjim.2009.24.3.227","article-title":"Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes","volume":"24","author":"Kim","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.numecd.2011.11.005_bib50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-11-2","article-title":"Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group","volume":"11","author":"Peyser","year":"2010","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.numecd.2011.11.005_bib51","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjmed.2003.07.023","article-title":"Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial","volume":"116","author":"Aljabri","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.numecd.2011.11.005_bib52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0009-9236(97)90068-0","article-title":"Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes","volume":"62","author":"Sironi","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2011.11.005_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00416.x","article-title":"A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.numecd.2011.11.005_bib54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.amjhyper.2004.09.010","article-title":"The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Sarafidis","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.numecd.2011.11.005_bib55","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2011.11.005_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.clpt.6100146","article-title":"Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus","volume":"82","author":"Berria","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2011.11.005_bib57","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1517\/14656566.2010.495119","article-title":"Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis","volume":"11","author":"Abe","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.numecd.2011.11.005_bib58","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","article-title":"Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation","volume":"146","author":"Ali","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.numecd.2011.11.005_bib59","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1210\/jc.2009-2638","article-title":"Thiazolidinediones and fractures: evidence from translating research into action for diabetes","volume":"95","author":"Bilik","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2011.11.005_bib60","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","article-title":"Use of thiazolidinediones and fracture risk","volume":"168","author":"Meier","year":"2008","journal-title":"Arch Intern Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475311002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475311002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:08:06Z","timestamp":1760544486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475311002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0939475311002626"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2011.11.005","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glitazones in chronic kidney disease: Potential and concerns","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2011.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}